These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 31270529)

  • 1. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
    Guedeney P; Giustino G; Sorrentino S; Claessen BE; Camaj A; Kalkman DN; Vogel B; Sartori S; De Rosa S; Baber U; Indolfi C; Montalescot G; Dangas GD; Rosenson RS; Pocock SJ; Mehran R
    Eur Heart J; 2022 Feb; 43(7):e17-e25. PubMed ID: 31270529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
    Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
    PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis.
    Guedeney P; Sorrentino S; Giustino G; Chapelle C; Laporte S; Claessen BE; Ollier E; Camaj A; Kalkman DN; Vogel B; De Rosa S; Indolfi C; Lattuca B; Zeitouni M; Kerneis M; Silvain J; Collet JP; Mehran R; Montalescot G
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):225-235. PubMed ID: 32275743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis.
    Bodapati AP; Hanif A; Okafor DK; Katyal G; Kaur G; Ashraf H; Khan S
    Cureus; 2023 Oct; 15(10):e46605. PubMed ID: 37937036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat.
    Wang HF; Mao YC; Xu XY; Zhao SY; Han DD; Ge SY; Song K; Geng C; Tian QB
    Front Cardiovasc Med; 2022; 9():1016802. PubMed ID: 36531722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
    Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
    Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of alirocumab/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials.
    Dai H; Zhu Y; Chen Z; Yan R; Liu J; He Z; Zhang L; Zhang F; Yan S
    Endokrynol Pol; 2023; 74(3):234-242. PubMed ID: 37335067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
    Rivera FB; Cha SW; Magalong JV; Bantayan NRB; Cruz LLA; Arias-Aguirre E; Aguirre Z; Varona MC; Co EMF; Lumbang GNO; Enkhmaa B
    Curr Med Res Opin; 2024 Jul; 40(7):1103-1121. PubMed ID: 38836510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.
    Shin KH; Choi HD
    Int J Clin Pharmacol Ther; 2024 Jun; 62(6):250-258. PubMed ID: 38529927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials.
    Geng Q; Li X; Sun Q; Wang Z
    Cardiol J; 2022; 29(4):574-581. PubMed ID: 34581425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Chen Q; Wu G; Li C; Qin X; Liu R; Zhang M
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):343-353. PubMed ID: 31823301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.
    Hirsh Raccah B; Yanovsky A; Treves N; Rotshild V; Renoux C; Danenberg H; Eliaz R; Matok I
    Int J Cardiol; 2021 Jul; 335():7-14. PubMed ID: 33892045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.
    Zhang XL; Zhu QQ; Zhu L; Chen JZ; Chen QH; Li GN; Xie J; Kang LN; Xu B
    BMC Med; 2015 Jun; 13():123. PubMed ID: 26099511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons.
    Bajaj NS; Patel N; Kalra R; Ahmad A; Venkatraman A; Arora G; Arora P
    Eur Heart J Qual Care Clin Outcomes; 2018 Apr; 4(2):132-141. PubMed ID: 29121222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.
    Karatasakis A; Danek BA; Karacsonyi J; Rangan BV; Roesle MK; Knickelbine T; Miedema MD; Khalili H; Ahmad Z; Abdullah S; Banerjee S; Brilakis ES
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29223954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Imbalzano E; Ilardi F; Orlando L; Pintaudi B; Savarese G; Rosano G
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):318-327. PubMed ID: 36972610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis.
    Ghasempour G; Zamani-Garmsiri F; Shaikhnia F; Soleimani AA; Hosseini Fard SR; Leila J; Teimuri S; Parvaz N; Mohammadi P; Najafi M
    Curr Med Chem; 2024; 31(2):223-241. PubMed ID: 36852818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.